+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2019

  • ID: 4866603
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 151 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 3SBio Inc
  • Biotest AG
  • Enzene Biosciences Ltd
  • HanAll Biopharma Co Ltd
  • Intas Pharmaceuticals Ltd
  • Pfizer Inc
  • MORE
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Thrombocytopenic Purpura - Pipeline Review, H2 2019, provides an overview of the Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline landscape.

Idiopathic thrombocytopenic purpura is a bleeding disorder in which the immune system destroys platelets, which play important role in normal blood clotting. Symptoms include blood in urine or stools, fatigue, spontaneous bleeding from nose and superficial bleeding into skin that appears as a rash of pinpoint sized reddish purple spots, usually on lower legs.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Idiopathic Thrombocytopenic Purpura - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 5, 10, 9, 1 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Idiopathic Thrombocytopenic Purpura (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Idiopathic Thrombocytopenic Purpura (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Hematological Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 3SBio Inc
  • Biotest AG
  • Enzene Biosciences Ltd
  • HanAll Biopharma Co Ltd
  • Intas Pharmaceuticals Ltd
  • Pfizer Inc
  • MORE
Introduction
Report Coverage
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Companies Involved in Therapeutics Development
3SBio Inc
Amgen Inc
Argenx SE
Biotest AG
Clover Biopharmaceuticals
CSL Ltd
Enzene Biosciences Ltd
Genosco Inc
Genzyme Corp
HanAll Biopharma Co Ltd
Hutchison MediPharma Ltd
Immunomedics Inc
Intas Pharmaceuticals Ltd
Jiangsu Hengrui Medicine Co Ltd
Kezar Life Sciences Inc
Momenta Pharmaceuticals Inc
Novartis AG
Pfizer Inc
Pharmagenesis Inc
Pharmapraxis
Principia Biopharma Inc
Protalex Inc
Qilu Pharmaceutical Co Ltd
Rigel Pharmaceuticals Inc
Sichuan Kelun Pharmaceutical Co Ltd
Taiho Pharmaceutical Co Ltd
UCB SA
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Drug Profiles
batoclimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BT-595 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSL-730 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
efgartigimod alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eltrombopag olamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fostamatinib disodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hetrombopag Olamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMPL-523 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KLM-465 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KZR-616 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-254 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nipocalimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06755347 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PHN-013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRN-1008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRTX-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QL-0911 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize Thrombopoietin Receptor for Idiopathic Thrombocytopenic Purpura - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
romiplostim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
romiplostim biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rozanolixizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCB-219 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKIO-703 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sutimlimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAS-05567 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
thrombopoietin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veltuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Universities/Institutes, H2 2019
Table 5: Products under Development by Companies, H2 2019
Table 6: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 7: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 8: Products under Development by Universities/Institutes, H2 2019
Table 9: Number of Products by Stage and Target, H2 2019
Table 10: Number of Products by Stage and Mechanism of Action, H2 2019
Table 11: Number of Products by Stage and Route of Administration, H2 2019
Table 12: Number of Products by Stage and Molecule Type, H2 2019
Table 13: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by 3SBio Inc, H2 2019
Table 14: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Amgen Inc, H2 2019
Table 15: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Argenx SE, H2 2019
Table 16: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Biotest AG, H2 2019
Table 17: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Clover Biopharmaceuticals, H2 2019
Table 18: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by CSL Ltd, H2 2019
Table 19: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Enzene Biosciences Ltd, H2 2019
Table 20: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Genosco Inc, H2 2019
Table 21: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Genzyme Corp, H2 2019
Table 22: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by HanAll Biopharma Co Ltd, H2 2019
Table 23: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Hutchison MediPharma Ltd, H2 2019
Table 24: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Immunomedics Inc, H2 2019
Table 25: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Intas Pharmaceuticals Ltd, H2 2019
Table 26: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
Table 27: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Kezar Life Sciences Inc, H2 2019
Table 28: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Momenta Pharmaceuticals Inc, H2 2019
Table 29: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Novartis AG, H2 2019
Table 30: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pfizer Inc, H2 2019
Table 31: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pharmagenesis Inc, H2 2019
Table 32: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pharmapraxis, H2 2019
Table 33: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Principia Biopharma Inc, H2 2019
Table 34: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Protalex Inc, H2 2019
Table 35: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Qilu Pharmaceutical Co Ltd, H2 2019
Table 36: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Rigel Pharmaceuticals Inc, H2 2019
Table 37: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, H2 2019
Table 38: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2019
Table 39: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by UCB SA, H2 2019
Table 40: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects, H2 2019
Table 41: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects, H2 2019 (Contd..1), H2 2019
Table 42: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products, H2 2019

List of Figures
Figure 1: Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products by Top 10 Targets, H2 2019
Figure 4: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 5: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Top 10 Routes of Administration, H2 2019
Figure 8: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Molecule Types, H2 2019
Figure 10: Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 3SBio Inc
  • Amgen Inc
  • Argenx SE
  • Biotest AG
  • Clover Biopharmaceuticals
  • CSL Ltd
  • Enzene Biosciences Ltd
  • Genosco Inc
  • Genzyme Corp
  • HanAll Biopharma Co Ltd
  • Hutchison MediPharma Ltd
  • Immunomedics Inc
  • Intas Pharmaceuticals Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Kezar Life Sciences Inc
  • Momenta Pharmaceuticals Inc
  • Novartis AG
  • Pfizer Inc
  • Pharmagenesis Inc
  • Pharmapraxis
  • Principia Biopharma Inc
  • Protalex Inc
  • Qilu Pharmaceutical Co Ltd
  • Rigel Pharmaceuticals Inc
  • Sichuan Kelun Pharmaceutical Co Ltd
  • Taiho Pharmaceutical Co Ltd
  • UCB SA
Note: Product cover images may vary from those shown
Adroll
adroll